2 research outputs found
CO-MORBIDITY OF CARDIOVASCULAR DISEASES AND RHEUMATOID ARTHRITIS
No full textRheumatoid Arthritis (RA) is a chronic disease related to swelling of joints which leads to restriction in movement due to pain and deformity in mainly in feet, ankle, wrist and fingers. It is an autoimmune disease and the manifestations caused due to its occurrence are not clearly understood. In today’s time, it has been observed that comorbid conditions account for most of the deaths as they influence the outcome of RA and limit therapeutic options. The most common comorbid conditions which are diagnosed in RA patients are generally cardiovascular abnormalities, several infections, certain mental disorders and malignancies. Among which cardiovascular comorbid diseases are the most common kind relating to disorders of heart and blood vessel that eventually leads to severe conditions like angina, myocardial infarction (MI), stroke, rheumatic heart disease and many more. RA affects the quality of life of patients directly or indirectly but it mainly shows a significant increase in the prevalence of cardiovascular diseases. Hence, it is essential to diagnose and understand about the related manifestations when one is suffering from Rheumatoid Arthritis. These studies will aid to make better treatment and management strategies. Hence, an attempt has been made in this review article regarding the epidemiology, impact of both the diseases and related risk factors. It also gives information in brief about the pathological causes of the comorbidity and summarizes measures that may be used in the prevention and treatment of these conditions.</jats:p
ORAL BIOAVAILABILITY ENHANCEMEMENT OF BROMOCRYPTINE MESYLATE BY SELF-MICRO EMULSIFYING DRUG DELIVERY SYSTEM (SMEDDS)
No full textObjective: The purpose of this work was to enhance oral bioavailability of Bromocryptine Mesylate by preparing SMEDDS (self-micro emulsifying drug delivery system)Methods: Screening of oils, surfactants and co-surfactants were done by solubility study & pseudo ternary diagram. The batches of Bromocryptine Mesylate (BM)–SMEDDS were prepared and evaluated for droplet size analysis, poly dispensability index (PDI), robustness to dilution, zeta potential, in vitro dissolution. The optimized batch was compared with commercially available quick release tablets of BM (Brainstar®, 0.8 mg/tablet) by in vivo study (Pharmacodynamic study in rats).Results: Based on the drug\u27s solubility study, Akoline MCM, Tween80 and PEG400 were selected as oil, surfactant and co-surfactant, respectively. By pseudo ternary diagram, the components\u27 ratios were screened. In vitro drug release of the optimized batch was lower than the commercial preparation but in in vivo study, optimized batch was similar with commercial tablets.Conclusion: From the study, it was concluded that the group treated with optimized BM-SMEDDS showed better and sustained reduction in blood sugar as compared to control group and the group treated with marketed formulation, indicated improvement in bioavailability of drug. Keywords: Bromocryptine Mesylate, Type–II Diabetes, Self micro emulsifying drug delivery system, Bioavailability, Pharmacodynamic stud
